Project Grant R01HL172820
Award Date
8/15/25
Completion Date
5/31/29
Dollars Obligated
$664K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Seattle, WA 98195, USA
Similar Awards
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $694,754 to The Washington University in St. Louis to conduct research on understanding the molecular and cellular mechanisms underlying cardiomyopathies and identifying potential therapeutic interventions. The key objectives are to: 1) determine if patient mutations in the troponin gene can be grouped based on common molecular...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $135,840 to the University of Washington from September 1, 2024 to August 31, 2026. The project will investigate the mechanisms of cardiac contractile dysfunction across multiple scales using a combined computational and experimental platform. Specifically, the work will focus on how structural perturbations to the myosin protein affect its...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), provides $116,250.00 to the Regents of the University of Minnesota to conduct research on identifying the underlying causes of cardiomyopathy. The research aims to evaluate the use of cardiac magnetic resonance imaging to reclassify the causes of cardiomyopathy, which could lead to more accurate diagnosis and appropriate...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $126,306 Project Grant under CFDA 93.837 - Cardiovascular Diseases Research to the University of Washington. The goal of this 2-year award is to establish a system to accelerate the reclassification of variants of unknown significance in the MYH7 gene, which cause hypertrophic cardiomyopathy, and determine the role of genetic modifiers that influence the severity of this disease. The research will utilize human induced pluripotent...
This Project Grant award of $601,563 was provided by the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), with a project period from September 1, 2024 to August 31, 2027. The award supports research to investigate the pathogenic roles and molecular mechanisms of the histone lysine demethylases KDM5A and KDM5B in the development and progression of heart failure, with a focus on hereditary cardiomyopathies like Lamin...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research (CFDA 93.837) program supports research into the regulation of the autophagy pathway and its relationship to cardiomyopathy and heart failure. The $2,185,454 award to Tufts Medical Center Parent, Inc. will fund a 4-year study investigating the mechanistic basis of a genetic variant (FHOD3V1151I) associated with hypertrophic cardiomyopathy. Key objectives...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $817,208 to The Broad Institute, Inc. to investigate the genetic basis and underlying mechanisms of heart failure. The research leverages high-throughput cellular analysis techniques, including cell painting and Perturb-seq, to functionally characterize genetic variants associated with heart failure risk. The goal is to rapidly...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $771,750 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of California, Los Angeles (UCLA) to investigate the role of macrophages in regulating cardiac muscle metabolism after myocardial infarction. The project aims to shed novel insights into how macrophages recruited to the infarcted heart disrupt cardiac muscle metabolism and lead to decreased NAD pools, which play a critical...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $167,400 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the Regents of the University of Michigan. The 5-year grant, which commenced on May 15, 2025, supports research by Dr. Joshua Meisner, a pediatric cardiologist and physician-scientist, to elucidate the mechanical and metabolic pathways underlying hypertrophic cardiomyopathy (HCM) caused by MYBPC3 gene mutations. The research aims to develop...
The federal Project Grant award of $621,546.00 was granted on July 20, 2025 by the National Heart Lung and Blood Institute (NHLBI), under the CFDA 93.837 Cardiovascular Diseases Research program. The grant supports research focused on observing the catalytic subunit of cAMP-dependent protein kinase A (PKA-C) at the single molecule level, to understand its role in normal heart function and cardiac disease states. Key objectives include: Engineering a single-walled carbon nanotube field effect...